Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity

C. E. Jackson, R. J. Barohn, G. Gronseth, S. Pandya, L. Herbelin, Rabi Tawil, Robert Griggs, Charles Thornton, John Kissel, Jerry Mendell, Angela Genge, George Karpati, Carlayne Jackson, Michael Rose, Anthony Amato, Richard Barohn, David Saperstein, Michael P. McDermott, Shree Pandya, Deborah WahlenWendy King, Adriana Venturini, Deborah Myers, Samantha Prisley, Michelle Tagerman, Meredith O'Brien, Laura Herbelin, Lynn Cos, Karen Downing, Roza Plesiak, Frieda Barefield, Catherine Morrison, Hannah Briemberg, Robert Holloway, Derick Peterson, Joanne Janciuras, William Martens, Christine Blood

Research output: Contribution to journalArticlepeer-review

111 Scopus citations

Abstract

We developed a disease-specific, 10-point functional rating scale for patients with inclusion body myositis (IBMFRS). The IBMFRS was utilized as a secondary outcome measure in a multicenter pilot trial of the clinical safety and tolerability of high-dose beta interferon-1a. In this trial, 28 IBM patients completed the IBMFRS at baseline and monthly for 6 months. The IBMFRS showed statistically significant correlations (P < 0.001) with maximal voluntary isometric contraction, manual muscle testing, handgrip dynamometry, and the amyotrophic lateral sclerosis (ALS) functional rating scale (ALSPRS). Compared to these other outcome measures, the IBMFRS was also the most sensitive measure of change over the course of the study.

Original languageEnglish (US)
Pages (from-to)473-476
Number of pages4
JournalMuscle and Nerve
Volume37
Issue number4
DOIs
StatePublished - Apr 1 2008

Keywords

  • Beta-interferon
  • Functional scale
  • Inclusion-body myositis
  • Outcome measure
  • Quality of life

ASJC Scopus subject areas

  • Clinical Neurology
  • Physiology (medical)
  • Cellular and Molecular Neuroscience
  • Physiology

Fingerprint

Dive into the research topics of 'Inclusion body myositis functional rating scale: A reliable and valid measure of disease severity'. Together they form a unique fingerprint.

Cite this